The Fixed Combination Efficacy Assessment in Patients with Secondary Neovascular Glaucoma and Diabetes Mellitus

Author(s): D. V. Lipatov, T. A. Chistyakov, A. G. Kuzmin, A. A. Tolkacheva.

Journal Name: Current Diabetes Reviews

Volume 11 , Issue 4 , 2015

Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

Purpose: To assess IOP-lowering efficacy of bimatoprost/timolol fixed combination (Ganfort®) in patients with diabetes mellitus (DM) and uncontrolled secondary neovascular glaucoma (NG).

Materials and Methods: Fifty patients (51 eyes) with uncontrolled secondary neovascular glaucoma and diabetes mellitus were enrolled in the study. All patients with an uncontrolled IOP have been proposed to switch current IOP-lowering therapy to Ganfort®. In case target IOP level was not reached filtration surgery was recommended. Ganfort® administration - once a day in the morning.

Results: IOP-lowering has been observed in all patients when switched to Ganfort®. Mean IOP level was almost 3-x lower versus baseline in 72.5% of patients (37 eyes). The patients achieved target IOP of 15-17 mmHg. As a result, no surgical intervention was required. Significant IOP-lowering has been observed in another group of patients (14 eyes, 27.5 %) nevertheless due to glaucoma progression, these patients are still subjected to surgical treatment.

Conclusion: IOP-lowering fixed combination Ganfort® (Allergan) can be used in patients with secondary neovascular glaucoma and diabetes mellitus as a drug of choice to control the IOP level. Even in cases when target IOP is not achieved, Ganfort® can be administered in pre-operative period and helps to reduce postoperative complications.

Keywords: Neovascular glaucoma, diabetes mellitus, intraocular pressure, diabetic glaucoma.

Rights & PermissionsPrintExport Cite as


Article Details

VOLUME: 11
ISSUE: 4
Year: 2015
Page: [281 - 284]
Pages: 4
DOI: 10.2174/1573399811666150525121225
Price: $58

Article Metrics

PDF: 24